Myeloid PTEN loss affects the therapeutic response by promoting stress granule assembly and impairing phagocytosis by macrophages in breast cancer
Data files
Jul 30, 2024 version files 168.90 KB
-
README.md
1.66 KB
-
stable_2-5.zip
167.23 KB
Abstract
Breast cancer (BRCA) has become the most common type of cancer in women. Improving the therapeutic response remains a challenge. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a classic tumour suppressor with emerging new functions discovered in recent years, and myeloid PTEN loss has been reported to impair antitumour immunity. In this study, we revealed a novel mechanism by which myeloid PTEN potentially affects antitumour immunity in BRCA. We detected accelerated stress granule (SG) assembly under oxidative stress in PTEN-deficient bone marrow-derived macrophages (BMDMs) through the EGR1-promoted upregulation of TIAL1 transcription. PI3K/AKT/mTOR (PAM) pathway activation also promoted SG formation. ATP consumption during SG assembly in BMDMs impaired the phagocytic ability of 4T1 cells, potentially contributing to the disruption of antitumour immunity. In a BRCA neoadjuvant cohort, we observed a poorer response in myeloid PTENlow patients with G3BP1 aggregating as SGs in CD68+ cells, a finding that was consistent with the observation in our study that PTEN-deficient macrophages tended to more readily assemble SGs with impaired phagocytosis. Our results revealed the unconventional impact of SGs on BMDMs and might provide new perspectives on drug resistance and therapeutic strategies for the treatment of BRCA patients.
(https://doi.org/10.5061/dryad.djh9w0w82 )
This is the resource data of Supplementary table 2,3,4,5.
(N/A): Not Applicable. Empty cells which have no data to display or there’s no specific value for the cell.
Description of the data and file structure
Supplementary Table 2. is a summarization of detailed information, including the patient number, MP grade, and MOD of specific targets.
No: serial number of specimens
H: high
L: low
n: number of specimens
Supplementary Table 3 was the results of all the transcription factors screened out from the DEGs between Ptenf/f and Ptenmko BMDMs.
TF: transcription factors
DEGs:differentially expressed genes
Supplementary Table 4 was the results of the identified 6 potential TFs of TIAL1 among Supplementary Table 3 in BMDMs which were predicted using ChEA software and the ChIP-X database.
TF: transcription factors
DEGs:differentially expressed genes
DEGs-TF:the transcription factors screened out of the differentially expressed genes
TIAL1-TF:the predicted transcription factors of TIAL1
DEGs-TF | TIAL1-TF(p): the potential transcription factors of TIAL1 in macrophages |
Supplementary Table 5 was the prediction results of potential binding sites of TILA1 using JASPAR software.
Here we submitted the original data of Detailed information, including the patient number, MP grade, and MOD of specific targets which is summarized in Supplementary Table 2; the screened transcription factors among the DEGs between Ptenf/f and Ptenmko BMDMs as Supplementary Table 3; the jVenn results of 6 potential transcription factors of TIAL1 as Supplementary Table 4 and the potential binding sites of TIAL1 using JASPAR software as Supplementary Table 5.